Belatacept utilization recommendations: An expert position

Expert Opinion on Drug Safety

Volumn 12, Issue 1, 2013, Pages 111-122

  Grinyó, Josep M ^a   Budde, Klemens ^b   Citterio, Franco ^c   Charpentier, Bernard ^d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CATHOLIC UNIVERSITY   (Italy)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Belatacept; Immunosuppressive therapy; Recommendations; Renal transplant

Indexed keywords

BASILIXIMAB; BELATACEPT; INTERLEUKIN 2;

ANTIVIRAL THERAPY; CHRONIC ALLOGRAFT NEPHROPATHY; DELAYED GRAFT FUNCTION; DRUG MONITORING; DRUG SAFETY; DRUG UTILIZATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; WEIGHT FLUCTUATION;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871483034     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.748747     Document Type: Review

References (80)

1. Resende L, Guerra J, Santana A, et al. First year renal function as a predictor of kidney allograft outcome. Transplant Proc 2009;41:846-8
2. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002;62:311-18
3. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001;38(Suppl 6):S44-50
4. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95
5. 2008 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998 -2007. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; Rockville, MD
6. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003;75:1291-5
7. Mathis AS, Dave N, Knipp GT, et al. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004;61:565-85
8. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-Analysis and meta-regression of randomised trial data. BMJ 2005;331:810-21
9. Roland M, Gatault P, Doute C, et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008;21:523-30
10. Myers BD, Ross J, Newton L, et al. Cyclosporine-Associated chronic nephropathy. N Engl J Med 1984;311:699-705
11. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557-65
12. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508
13. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69:2227-43
14. Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant 2011;11(4):687-92
15. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90(1):68-74
16. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75
17. Ka?lble T, Alcaraz A, Budde K, et al. Guidelines on renal transplantation. Uroweb 2012. Available from: http://www.uroweb.org/gls/pdf/ Renal% 20Transplantation%202010.pdf [Last accessed 13 June 2012]
18. Baczkowska T, Durlik M. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients. Pol Arch Med Wewn 2009;119:318-25
19. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:1-15
20. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-Affinity variant of CTLA4-lg with potent immunosuppressive properties. Am J Transplant 2005;5:443-53
21. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006;6:876-83
22. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998;18:389-418
23. Wojciechowski D, Vincenti F. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept. Curr Opin Organ Transplant 2010; [Epub ahead of print]
24. We'clawiak H, Kamar N, Ould-Mohamed A, et al. Biological agents in kidney transplantation: belatacept is entering the field. Expert Opin Biol Ther 2010;10:1501-8
25. Poirier N, Blancho G, Vanhove B. Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker. Immunotherapy2010;2:625-36
26. Tullius SG, Sayegh MH, Remuzzi G. Organ quality determines outcome after kidney transplantation. Eur Renal Dis 2007;1:51-4
27. Audard V, Matignon M, Dahan K, et al. Renal transplantation from extended criteria cadaveric donors: problems and perspectives overview. Transpl Int 2008;21:11-17
28. Keitel E, Michelon T, dos Santos AF, et al. Renal transplants using expanded cadaver donor criteria. Ann Transplant 2004;9:23-4
29. Metzger RA, Delmonico FL, Feng S, et al. Expanded criteria donors for kidney transplantation. Am J Transplant 2003;3(Suppl 4):114-25
30. Saidi RF, Elias N, Kawai T, et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007;7:2769-74
31. Diet C, Audard V, Roudot-Thoraval F, et al. Immunological risk in recipients of kidney transplants from extended criteria donors. Nephrol Dial Transplant 2010;25:2745-53
32. Vincenti F, Larsen C, Durrbach A, et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-81
33. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010;21:1587-96
34. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10:535-46
35. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10:547-57
36. Lenihan CR, O'Kelly P, Mohan P, et al. MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function. Ren Fail 2008;30:345-52
37. Salvadori M, Rosati A, Bock A, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation 2006;81:202-6
38. Medina Pestana J, Campistol JM, Rial MC, et al. Belatacept is associated with preservation of renal function and structure at 1 year compared to cyclosporine in extended criteria donor (ECD) kidney transplant patients (BENEFIT-EXT study) [abstract O-333]. Transpl Int 2009;22(Suppl 2):89
39. Larsen CP, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90:1528-35
40. Vincenti F, Larsen CP, Alberu J, et al.Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012;12(1):210-17
41. Durbach A, Grinyo J, Vanrenterghem Y,et al. Belatacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT Trial [abstract F568].
42. Durbach A, Citterio F, Mulloy L, et al. Renal function in patients treated with belatacept-or cyclosporine-based regimens at year 3 in the BENEFIT and BENEFIT-EXT Studies [abstract Sa521]. Annual Congress of the European Renal Association -European Dialysis and Transplant Association. (ERA EDTA); 23 -26 June 2011; Prague, Czech Republic
43. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010;90:1521-7
44. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011;91(9):987-3
45. Bristol-Myers Squibb Co. NULOJIX European Summary of Product Characteristics. 2011
46. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012;12(3):630-9
47. Larsen CP, Ginyo J, Medina Pestana J, et al. 3-Year safety profile of belatacept in kidney transplant Recipients from the BENEFIT and BENEFIT-EXT studies [abstract F564]. Annual Congress of the European Renal Association -European Dialysis and Transplant Association. (ERA EDTA); 23 -26 June 2011; Prague, Czech Republic
48. Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-Avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76
49. Bristol-Myers Squibb Co. Belatacept (BMS-224818). FDA's Cardiovascular and Renal Drugs Advisory Committee. Briefing Document for March 2010 Meeting; 25 January 2010
50. World Health Organization. Epstein Barr virus. 2008.Available from: http://www.who. int/vaccine-research/diseases/viral-cancers/en/index1. html#disease burden [Last accessed 12 July 2011]
51. Fritsche L, Vanrenterghem Y, Nordal KP, et al. Practice variations in the evaluation of adult candidates for cadaveric kidney transplantation: a survey of the European Transplant Centers. Transplantation 2000;70:1492-7
52. Kidney Disease: improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
53. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77:299-311
54. Allen U, Preiksaitis J. AST infectious diseases community of practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients.Am J Transplant 2009;9(Suppl 4):S87-96
55. Shen J, Gelb JS, Townsend RM, et al.Rationale for belatacept less intensive regimen in renal transplant recipients [abstract]. Am J Transplant 2011;11(Suppl 2):1096
56. Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant 2009;9:35-41
57. Morrissey PE, Reinert S, Yango A, et al. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. Transplant Proc 2005;37:2044-7
58. Shrestha BM, Haylor JL. Factors influencing long-term outcomes following renal transplantation: a review. J Nepal Med Assoc 2007;46:136-42
59. Butler JA, Peveler RC, Roderick P, et al. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004;77:786-9
60. Hansen R, Seifeldin R, Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant Proc 2007;39:1287-300
61. Bristol-Myers Squibb Co. Data on file
62. Grinyó JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009;24:2269-76
63. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009;87:926-33
64. Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus rescue therapy for renal allograft rejection -five-year experience. Transplantation 1997;63:223-8
65. Shen J, Zhou Z, Townsend R, et al. Predictable pharmacokinetics, pharmacodynamics, and exposure-response of belatacept avert the need of therapeutic drug monitoring [abstract]. Am J Transplant 2011;11(Suppl 2):1097
66. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29
67. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997;176:1462-7
68. Opelz G, Daniel V, Naujokat C, et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant -Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007;8:212-18
69. Larsen C, Charpentier B, Grinyo J, et al. One year safety profile of belatacept in kidney transplant patients from theBENEFIT nd BENEFIT-EXT studies. Am J Transplant 2009;9(Suppl 2):495
70. Walker RC. Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder. Transplant Proc 1995;27(5 Suppl 1):41
71. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007;41:1850-8
72. Kidney Disease: improving Global Outcomes (KDIGO). Managing kidney transplant recipients. 2010. Available from: http://www.kdigo.org/pdf/KDIGO-TX- NephsTool.pdf [Last accessed 23 May 2011]
73. Marce'n R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy, and infection. Drugs 2009;69:2227-43
74. Florman S, Becker T, Bresnahan B, et al. Three year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT & BENEFIT-EXT) [abstract]. Am J Transplant 2011;11(Suppl 2):229
75. Rostaing L, Neumayer HH, Reyes-Acevedo R, et al. Belatacept demonstrates superior composite patient/graft survival in diabetic kidney transplant recipients vs CsA: Results from the BENEFIT and BENEFIT-EXT studies [poster 106]. American Transplant Congress 2009; Boston, MA
76. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011;6:430-9
77. Grinyo J, Nainan G, Rial Mdel C, et al. Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: results from the long-term extension of a phase II study [abstract F567]. Annual Congress of the European Renal Association -European Dialysis and Transplant Association. (ERA EDTA);2011; Prague, Czech Republic
78. Pondrom S. The AJT report. Transplantation in Europe. Am J Transplant 2010;10:2563-4
79. Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008;3:491-504
80. Woo YM, McLean D, Kavanagh D, et al. The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation. J Nephrol 2002;15:380-6